The current prospective, non-interventional study (NIS) being conducted under the IgNITE umbrella protocol using primary data collection (PDC), aims to enhance understanding of real-world patient profiles, treatment patterns, and clinical outcomes among patients with IgAN treated with iptacopan or atrasentan in the real-world clinical care setting immediately from the time of drug launch. Furthermore, this study is planned to contribute to a global meta-analysis, to enable further analysis with greater statistical power, as well as exploration of similarities and differences of treatment use and outcomes between countries and regions. Each patient will be observed for 24 months
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Baseline demographic
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Time of IgAN diagnosis
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Baseline MEST-C
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Index Blood Pressure
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Index eGFR
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Index proteinuria
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Index hematuria
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Index serum albumin level
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Index creatinine level
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Number of participants by Index CKD stage
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Number of participants by ESKD status
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: History of dialysis and kidney transplant
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Baseline use of corticosteroids or targeted Budesonide for IgAN
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Baseline use of ACEi, ARB and SGLT2i treatments
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Baseline use of ERA, APRIL / APRIL-BAFF therapies, MMF, Hydroxychloroquine, nsMRA , Immunosuppressant
Timeframe: Index date (date of iptacopan or atrasentan initiation)
Baseline clinical characteristics: Number of participants who have participated in a clinical trial
Timeframe: Index date (date of iptacopan or atrasentan initiation)